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Purpose: There is a lack of sufficient data in comparison of optical coherence to-
mographic (OCT) findings between first- and second-generation drug-eluting 
stents (DES). Compared to first-generation (i.e., sirolimus- or paclitaxel-eluting 
stents), second-generation DESs (i.e., everolimus- or biolinx-based zotarolimus-
eluting stents) might have more favorable neointimal coverage. Materials and 
Methods: Follow-up OCT findings of 103 patients (119 lesions) treated with sec-
ond-generation DESs were compared with those of 139 patients (149 lesions) 
treated with first-generation DESs. The percentage of uncovered or malapposed 
struts, calculated as the ratio of uncovered or malapposed struts to total struts in all 
OCT cross-sections, respectively, was compared between the two groups. Results: 
Both DES groups showed similar suppression of neointimal hyperplasia (NIH) on 
OCT (mean NIH cross-sectional area; second- vs. first-generation=1.1±0.5 versus 
1.2±1.0 mm2, respectively, p=0.547). However, the percentage of uncovered struts 
of second-generation DESs was significantly smaller than that of first-generation 
DESs (3.8±4.8% vs.7.5±11.1%, respectively, p<0.001). The percentage of malap-
posed struts was also significantly smaller in second-generation DESs than in first-
generation DESs (0.4±1.6% vs.1.4±3.7%, respectively, p=0.005). In addition, in-
tra-stent thrombi were less frequently detected in second-generations DESs than in 
first-generation DESs (8% vs. 20%, respectively, p=0.004). Conclusion: This fol-
low-up OCT study showed that second-generation DESs characteristically had 
greater neointimal coverage than first-generation DESs.
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INTRODUCTION
With the introduction of first-generation drug-eluting stents (DES), a significant 
reduction in restenosis rates and an improvement in short-term clinical outcomes 
were reported.1,2 However, the use of first-generation DESs, e.g., sirolimus- and 
paclitaxel-eluting stents, has been shown to be strongly related with the occurrence 
of late or very late stent thrombosis, raising safety concerns.3,4 Several attempts to 
develop newer DESs have set out to prevent the occurrence of stent thrombosis by OCT Findings between First- vs. Second-Generation DESs
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tion, all patients received dual antiplatelet therapy with aspi-
rin and clopidogrel until the follow-up OCT was conducted. 
This study was approved by the Institutional Review Board 
of our institute, and written informed consent was obtained 
from each patient. 
OCT imaging and analysis
Detailed explanations regarding the OCT system and meth-
ods for imaging have been described in our previous stud-
ies.12,13 OCT examination was performed using a conven-
tional OCT system (Model M2 Cardiology Imaging System, 
LightLab Imaging, Westford, MA, USA) with a motorized 
pull-back system at 1.0 mm/s. The occlusion catheter was 
positioned proximal to the stent, and a 0.014-inch wire-type 
imaging catheter (ImageWire, LightLab Imaging) was po-
sitioned distal to the stent. During image acquisition, the 
occlusion balloon (Helios, Avantec Vascular, Sunnyvale, 
CA, USA) was inflated to 0.4-0.6 atm, and lactated Ringer’s 
solution was infused at a rate of 1.0 mL/s. The imaging wire 
was pulled from distal to proximal, and continuous images 
were acquired and stored digitally for subsequent analy-
sis.12,13 OCT analysis was performed by an independent in-
vestigator blinded to patient and procedural information. 
Cross-sectional OCT images were analyzed at 1-mm inter-
vals (every 15 frames). Stent and luminal cross-sectional ar-
eas (CSAs) were measured at 1-mm intervals, and NIH CSA 
was calculated as the stent CSA minus the luminal CSA. Per-
cent NIH CSA was calculated as NIH CSA×100/stent CSA. 
Mean values are reported in this study. The thickness of 
NIH, defined as the distance between the endoluminal sur-
face of neointima and the strut, was measured inside the 
struts at a line as perpendicular as possible to the neointima 
and strut.10 An uncovered strut was defined as having a NIH 
thickness of 0 μm.10,14 A malapposed strut was defined as a 
strut that had detached from the vessel wall (CypherTM, 
≥160 μm; TaxusTM, ≥130 μm; Endeavor Resolute®, ≥110 
μm; XienceTM, ≥100 μm).15,16 The percentage of uncovered 
or malapposed struts was investigated for evaluation of the 
healing responses of DESs as shown on OCT. The percent-
age of malapposed or uncovered struts in each stented le-
sion was calculated as the (number of malapposed or un-
covered struts/total number of struts in all cross-sections of 
the lesion)×100, respectively. Cross sections with major side 
branches (diameter ≥2 mm) were excluded from this analy-
sis. The neointimal coverage of stent struts in each cross-
section was evaluated, and then the percentage of uncov-
ered struts was analyzed and compared between the two 
modifying the eluted drugs, drug carrying systems, and stent 
design. Of these, second-generation DESs, e.g., everolim-
us-eluting stents (EES) and Biolinx-based zotarolimus-elut-
ing stents (Bx-ZES), have been reported to suppress neo-
intima hyperplasia (NIH) effectively and simultaneously 
demonstrate favorable long-term outcomes.5-9 Optical co-
herence tomography (OCT) has enabled researchers to 
evaluate neointimal coverage of DESs in detail, even at the 
strut level.10,11 However, no sufficient OCT data has been 
reported comparing neointimal coverage between first- and 
second-generation DESs. Therefore, using OCT, we sought 
to compare healing responses, including neointimal cover-
age, between the two groups.
MATERIALS AND METHODS
　　　
Study population
We used data submitted to the Yonsei OCT registry, evaluat-
ing neointimal coverage in patients who underwent coro-
nary stent implantation for de novo lesions.12,13 General ex-
clusion criteria for the follow-up OCT study were as follows: 
1) untreated significant left main coronary artery disease, 2) 
apparent congestive heart failure, 3) renal insufficiency 
(baseline creatinine ≥2.0 mg/dL), and 4) lesions unsuitable 
for OCT imaging (vessel size ≥3.5 mm or lesions within 10 
mm of the ostium of a major epicardial artery). Between 
September 2007 and October 2010, a total of 242 patients 
with 268 lesions were selected from the OCT registry data-
base. Inclusion criteria of the current study comprised le-
sions treated with EES, Bx-ZES, sirolimus- or paclitaxel-
eluting stents, as well as those followed with a follow-up 
OCT examination at 12±4 months after stent implantation. 
Exclusion criteria were 1) bifurcation treated with 2-stent 
techniques, 2) angiographic evidence of restenosis, 3) le-
sions with repeated revascularization, 4) bare-metal stent 
implantation, and 5) poor OCT image quality. Second-gen-
eration DESs were deployed in 103 patients for 119 lesions 
including EES (Xience VTM, Abbott Vascular, Santa Clara, 
CA, USA) and Bx-ZES (Endeavor Resolute®, Medtronic, 
Santa Rosa, CA, USA), while first-generation DESs were 
implanted in 139 patients for 149 lesions including sirolim-
us-eluting stents (CypherTM, Cordis, Miami, FL, USA) and 
paclitaxel-eluting stents (TaxusTM, Boston scientific, Natick, 
MA, USA). DES implantation was performed using current, 
conventional techniques, and the choice of DES was made 
according to the operators’ discretion. After DES implanta-Byeong-Keuk Kim, et al.
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of p<0.05 was considered statistically significant.
RESULTS
 
Baseline clinical characteristics are shown in Table 1. There 
were no significant differences in baseline clinical charac-
teristics between the two groups. Baseline angiographic 
and procedural characteristics are listed in Table 2. There 
were also no significant differences in baseline angiograph-
ic and procedural characteristics between the two groups.
Table 3 summarizes the OCT findings of both groups. 
There were no significant differences in mean lumen and 
stent CSA, as well as time to follow-up OCT (days) be-
tween the two groups. Although both groups showed a 
nearly similar suppression of NIH, the percentage of un-
covered struts of second-generation DESs was significantly 
smaller than that of first-generation DESs (3.8±4.8% vs. 
7.5±11.1%, respectively, p<0.001). The percentage of 
malapposed struts was also significantly smaller in second-
generation DESs than in first-generation DESs (0.4±1.6% 
vs. 1.4±3.7%, respectively, p=0.005). In addition, intra-
stent thrombi were less frequently detected in second-gen-
erations DESs than in first-generation DESs (8% vs. 20%, 
respectively, p=0.004). 
groups. Intra-stent thrombi were defined as a signal-rich, 
low-backscattering protrusions or high-backscattering pro-
trusions inside the lumen of the artery with signal-free 
shadowing on OCT images (dimension ≥250 μm).13
Angiographic analysis
Quantitative coronary angiography analysis was performed 
using an offline quantitative coronary angiography system 
(CASS system II, Pie Medical Imaging, Nuenen, the Neth-
erlands) before and after stent implantation and at the fol-
low-up angiogram. The minimal luminal diameter of the 
coronary lesions treated with DESs and a reference diame-
ter were measured in the view that was the most severe and 
not foreshortened.
Statistical analysis
All statistical analyses were performed using the Statistical 
Analysis System software (SAS; 9.1.3., SAS Institute, Cary, 
NC, USA). Categorical data were presented as a number (%) 
and compared with Chi-square statistics or Fisher’s exact test. 
Continuous data were presented as mean±standard deviation 
and compared with Student’s t-test. Comparisons among the 
four different DESs were performed by analysis of variance 
with post-hoc analysis by the Bonferroni method. If the distri-
butions were skewed, a non-parametric test was used. A value 
Table 1. Baseline Clinical Characteristics 
Variables First-generation drug-eluting 
stents (n=139)
Second-generation drug-eluting 
stents (n=103) p value
Age, yrs 61±10 62±11 0.584
Men, n (%)   91 (66)   69 (67) 0.890
Hypertension, n (%)   69 (50)   59 (57) 0.235
Diabetes mellitus, n (%)   46 (33)   30 (29) 0.576
Dyslipidemia, n (%)   42 (30)   26 (25) 0.470
Current smokers, n (%)   15 (11)   14 (14) 0.124
Previous MI, n (%) 10 (7)   4 (4) 0.089
Clinical presentation, n (%) 0.780
    Stable angina    53 (38)   41 (40)
    Unstable angina   38 (27)   32 (31)
    Non-ST elevation MI    21 (15)   13 (13)
    ST-elevation MI    27 (19)   16 (17)
Medications at index procedure, n (%)
    Aspirin   139 (100)   102 (100) 1.000
    Clopidogrel 138 (99) 101 (98) 1.000
    Beta-blockers 115 (83)   86 (83) 0.856
    ACEI or ARB 100 (72)   80 (78) 0.279
    Statins 137 (99) 101 (98) 1.000
MI, myocardial infarction; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; SD, standard deviation.
Values are expressed as mean±SD for quantitative variables or as n (%) for qualitative variables.OCT Findings between First- vs. Second-Generation DESs
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growth was not different from that of first-generation DESs. 
As concerns regarding the safety issues of first-genera-
tion DESs have increased, newly developing DESs have fo-
cused more on safety with a similar efficacy to that of first-
generation DESs through the long-term follow-up studies.3,4 
Among many newly developed DESs, EES and Bx-ZES 
have been shown to have both excellent efficacy and safe-
ty.5-9 Clinical Evaluation of the Xience V Everolimus Elut-
ing Coronary Stent System in the Treatment of Patients 
DISCUSSION
This follow-up OCT study demonstrated that second-genera-
tion DESs lead to a lower percentage of uncovered and 
malapposed struts, as well as a lower incidence of intra-stent 
thrombi, compared with first-generation DESs. In spite of su-
perior healing responses of second-generation DESs, the effi-
cacy of second-generation DESs in the suppression of NIH 
Table 2. Baseline Angiographic and Procedural Characteristics
Variables First-generation DESs 
(n=149)
Second-generation DESs  
(n=119) p value
Lesion morphology, type C, n (%) 101 (68) 81 (68) 1.000
Lesion length (mm) 23.1±6.3 22.8±6.2 0.123
Stent diameter (mm)   2.95±0.30   2.91±0.29 0.306
Stent length (mm) 25.1±7.2 24.8±4.9 0.211
Types of implanted DES -
    Sirolimus-eluting stent, n (%)   89 (60) -
    Paclitaxel-eluting stents, n (%)   60 (40) -
    Everolimus-eluting stents, n (%) - 67 (56)
    Biolinx-based zotarolimus-eluting stents, n (%) - 52 (44)
Quantitative coronary angiography analysis
    Reference vessel diameter (mm)   2.78±0.44   2.80±0.50 0.515
    Pre-intervention MLD (mm)   0.74±0.49   0.80±0.48 0.232
    Post-intervention MLD (mm)   2.63±0.32   2.59±0.37 0.103
    Follow-up MLD (mm)   2.19±0.56   2.17±0.47 0.662
DES, drug-eluting stents; MLD, minimal lumen diameter; SD, standard deviation.
Values are expressed as mean±SD for quantitative variables or as n (%) for qualitative variables. 
Table 3. Follow-Up Optical Coherence Tomography Measurements
Variables First-generation DESs (n=149) Second-generation DESs (n=119) p value
Number of cross sections   3709   2665
Total number of analyzable struts 32972 23750
Time to follow-up OCT (days) 296±60 290±43   0.273
Mean stent CSA (mm
2)   7.1±1.7   7.0±1.6   0.925
Mean lumen CSA (mm
2)   5.9±1.6   5.9±1.7   0.923
Mean NIH CSA (mm
2)   1.2±1.0   1.1±0.5   0.547
Mean percent NIH CSA (%)   16.9±12.4 17.1±8.3   0.884
Mean NIH thickness (µm)   148±111 142±63   0.666
Percentage of uncovered struts, %     7.5±11.1   3.8±4.8 <0.001
Percentage of malapposed struts, %   1.4±3.7   0.4±1.6   0.005
Presence of intra-stent thrombi, n (%) 30 (20) 9 (8)   0.004
Comparisons among the DES Sirolimus-eluting 
stents (n=89)
Paclitaxel-eluting 
stents (n=60)
Everolimus-eluting 
stents (n=67)
Biolinx-based 
zotarolimus-eluting 
stents (n=52)
p value
Percentage of uncovered struts, % 10.2±12.9   3.5±6.0*  3.6±4.1*   3.9±5.6* <0.001
Percentage of malapposed struts, % 1.7±4.1 0.8±3.1 0.3±0.6
† 0.6±2.3   0.014
Presence of intra-stent thrombi, n (%) 25 (28) 5 (8)* 8 (12)
† 1 (2)* <0.001
CSA, cross-sectional area; DES, drug-eluting stent; NIH, neointimal hyperplasia; OCT, optical coherence tomography; SD, standard deviation. 
Values are expressed as mean±SD for quantitative variables or as n (%) for qualitative variables. 
*p<0.01 and 
†p<0.05 when compared to sirolimu-eluting stents. Byeong-Keuk Kim, et al.
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was significantly lower than that of first-generation DESs. 
Stent malapposition has been also regarded as an important 
predictor of DES thrombosis in intravascular ultrasound 
studies.20,21 DES type has been suggested as one of the most 
determining factors of stent malapposition.21,22 A difference 
in the incidence of stent malapposition dependent upon the 
type of DES might be associated with differences in long-
term outcomes. Namely, a lower rate of malapposition in 
second-generation DESs may translate to more favorable 
clinical outcomes after DES implantation thereof. 
Study limitations
This study has several limitations. First, selection bias might 
affect the results because this was a non-randomized regis-
try study. Second, because this study was not a controlled 
comparative one, direct comparisons among four different 
DESs could not be performed. However, there were no sig-
nificant differences in the baseline clinical and angiograph-
ic parameters between the two groups. Third, because the 
study population of the current study was free of major ad-
verse events after DES implantation until follow-up OCT, 
the lesions of this study might not represent those seen in 
real world practice. Fourth, in this study, the first-generation 
DES group, which consisted of sirolimus-eluting stents and 
paclitaxel-eluting stents, was compared with second-gener-
ation DESs. However, because sirolimus-eluting stents and 
paclitaxel-eluting stents showed different outcomes in some 
pathologic and imaging studies,12,13,23,24 careful attention 
must be given when interpreting the results. Finally, no clin-
ical follow-up data was provided due to the short duration 
of clinical follow-up after OCT evaluation. 
In conclusion, this follow-up OCT study showed that 
second-generation DESs characteristically had greater neo-
intimal coverage than first-generation DESs. For more defi-
nite conclusions, long term clinical and serial OCT follow-
up with a larger population will be needed in the future.
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with de novo Native Coronary Artery Lesions (SPIRIT) III 
randomized study showed that EES implantation resulted 
in a statistically significant reduction of angiographic late 
loss at 8-month follow-up and showed significantly im-
proved event-free survival, compared with implantation of 
paclitaxel-eluting stents at 2-year follow-up.5,6 In addition, 
compared with patients treated with paclitaxel-eluting 
stents, those treated with EES tended to have fewer epi-
sodes of late stent thrombosis at 1 and 2 years (0.2% versus 
1.0%; p=0.10) thereafter.6 Recently, Bx-ZES, which com-
prises a low-profile, thin-strut platform, and a Biolinx tri-
polymer, also showed favorable short-term angiographic 
outcomes with a comparable low late loss.7
Many potential mechanisms or factors are expected to be 
related with the favorable outcomes demonstrated in second-
generation DESs.5-8,17 Of these, the degree of reendothelial-
ization, regarded as the most powerful predictor of stent 
thrombosis, might be strongly related with better outcomes in 
DESs.11,18,19 Although some studies have evaluated neointi-
mal coverage for various types of DES, they were conducted 
as an autopsy or animal study.17,18 A new imaging tool, OCT, 
has enabled researchers to evaluate the reendothelialization 
of DES in live patients with a superior resolution capacity.10,11 
Therefore, using OCT, healing responses, including neointi-
mal coverage of stent struts, was evaluated between second-
generation and first-generation DESs in this study. 
In the current OCT study, the rate of uncovered struts as 
shown on OCT was significantly different between the two 
groups; second-generation DESs showed a higher % of un-
covered struts, meaning more complete neointimal cover-
age. However, the amount of NIH was similar between the 
first- and second-generation DESs. The superior nature of 
second-generation DESs, showing better endothelialization 
and healing responses compared with first-generation DESs, 
while maintaining similar efficacy represented by the sup-
pression of NIH on OCT or a low late loss on follow-up an-
giogram, might be caused by the unique components com-
prising DESs, including the use of novel drugs, superior 
biocompatibility and morphology of polymers, reduced 
polymer layers, and thin-strut design.17 As a result, newer 
DESs are both safe and have equal efficacy to first-genera-
tion DESs, and this study, in comparison of the OCT find-
ings thereof, suggests that second-generation DESs are 
close to the ideal DES.
The degree of stent malapposition, evaluated by OCT, 
was also significantly different between the two groups; the 
percentage of malapposed struts of second-generation DESs OCT Findings between First- vs. Second-Generation DESs
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